The fate of medium-chain fatty acids in very long-chain acyl‑CoA dehydrogenase deficiency (VLCADD): A matter of sex?

Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Nov;1864(11):1591-1605. doi: 10.1016/j.bbalip.2019.08.001. Epub 2019 Aug 5.

Abstract

Medium-chain-triglycerides (MCT) are widely applied in the treatment of long-chain fatty acid oxidation disorders (lcFAOD). Long-term treatment with MCT led to a sexually dimorphic response in the mouse model of very-long-chain-acyl-CoA-dehydrogenase-deficiency (VLCAD-/-) with the subsequent development of a metabolic syndrome in female mice. In order to evaluate the molecular mechanisms responsible for this sex specific response we performed a comprehensive metabolic phenotyping, SILAC-based quantitative proteomics and characterized the involved signaling pathways by western blot analysis and gene expression. WT and VLCAD-/- mice showed strong sex-dependent differences in basal metabolism and expression of proteins involved in the distinct metabolic pathways, even more prominent after treatment with octanoate. The investigation of molecular mechanisms responsible for the sexual dimorphisms delineated the selective activation of the ERK/mTORc1 signaling pathway leading to an increased biosynthesis and elongation of fatty acids in VLCAD-/- females. In contrast, octanoate induced the activation of ERK/PPARγ pathway and the subsequent upregulation of peroxisomal β‑oxidation in males. We here provide first evidence that sex has to be considered as important variable in disease phenotype. These findings may have implications on treatment strategies in the different sexes.

Keywords: ERK/mTORc1 signaling; MCT; PPARγ; Peroxisomal β‑oxidation; Sexual dimorphism; VLCADD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acyl-CoA Dehydrogenase, Long-Chain / deficiency*
  • Acyl-CoA Dehydrogenase, Long-Chain / genetics
  • Acyl-CoA Dehydrogenase, Long-Chain / metabolism*
  • Animals
  • Caprylates / metabolism
  • Caprylates / therapeutic use
  • Congenital Bone Marrow Failure Syndromes / genetics
  • Congenital Bone Marrow Failure Syndromes / metabolism*
  • Congenital Bone Marrow Failure Syndromes / therapy
  • Fatty Acids / metabolism*
  • Female
  • Gene Deletion
  • Humans
  • Lipid Metabolism, Inborn Errors / genetics
  • Lipid Metabolism, Inborn Errors / metabolism*
  • Lipid Metabolism, Inborn Errors / therapy
  • MAP Kinase Signaling System
  • Male
  • Mice
  • Mitochondrial Diseases / genetics
  • Mitochondrial Diseases / metabolism*
  • Mitochondrial Diseases / therapy
  • Muscular Diseases / genetics
  • Muscular Diseases / metabolism*
  • Muscular Diseases / therapy
  • Oxidation-Reduction
  • PPAR gamma / metabolism
  • Sex Factors
  • Signal Transduction
  • TOR Serine-Threonine Kinases / metabolism

Substances

  • Caprylates
  • Fatty Acids
  • PPAR gamma
  • Acyl-CoA Dehydrogenase, Long-Chain
  • TOR Serine-Threonine Kinases
  • octanoic acid

Supplementary concepts

  • VLCAD deficiency